Who is sponsoring NCT04590417?

NCT04590417 is sponsored by Thai Red Cross AIDS Research Centre.

What condition does NCT04590417 study?

NCT04590417 studies Drug Interaction.

What drugs are being tested in NCT04590417?

Interventions: Estradiol valerate 2 mg, cyproterone acetate 25 mg.

What is the status of NCT04590417?

NCT04590417 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2024-11-25 · How we verify

Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women

NCT04590417 NA ACTIVE_NOT_RECRUITING

Recent studies have showed that there were significant drug-drug interactions (DDI) from feminizing hormone therapy (FHT) towards emtricitabine/tenofovir disoproxil fumarate (F/TDF)-based pre-exposure prophylaxis (PrEP) among transgender women (TGW). New strategies for PrEP among TGW who use FHT are urgently needed. Because tenofovir alafenamide (TAF) can achieve higher intracellular TFV-DP levels with lower tenofovir plasma concentrations, it is promising that both plasma TFV and intracellular TFV-DP levels might not be significantly affected by FHT. The current study aims to determine the pharmacokinetics DDI between FHT and F/TAF-based PrEP among TGW.

Details

Lead sponsor	Thai Red Cross AIDS Research Centre
Phase	NA
Status	ACTIVE_NOT_RECRUITING
Enrolment	20
Start date	Mon Jan 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Drug Interaction

Interventions

Estradiol valerate 2 mg, cyproterone acetate 25 mg

Countries

Thailand